Skip to main content

Clinical trial 1206 - HNCG

A randomized phase II study to evaluate the efficacy and safety of Chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic, androgen receptor (AR) expressing, salivary gland cancer (SGCs)

Organ Oral cavity and lips
Trial status Trial closed for recruitment
Trial type
Interventional with experimental drug
Phase Trial phase 2
Academic trial Non
Sponsor EORTC
EudraCT Identifier 2013-000314-38
Inclusion criteria metastatic RECIST 1.1
Last update